NanoFace research group deals with the investigation of interactions at the nano-bio interface. We explore and open new avenues for more effective and safer nano-enabled systems motivated by the Safe- and Sustainable-by-Design (SSbD) approach.

We perform cutting edge research at the nano-bio interface to identify opportunities and risks of nanomaterials at early stage of development. Our main activities are focused on the:

  1. integration of existing knowledge to overcome knowledge gaps in nanomedicine and nanotoxicology;
  2. development and validation of science-based regulatory -relevant approaches to support innovative SSbD-based nano-enabled products;
  3. application, optimisation, standardisation and verification of advanced analytical, biological and computational tools and methods based on mechanistically-driven, animal-free assessment, high-throughput and high content analysis;
  4. establishment of a practical, robust, easy-to-use and cost-effective methodological framework for risk assessment of nanomaterials.

Our expertise is situated in a multidisciplinary environment covering chemistry, biochemistry, molecular biology, toxicology, risk assessment and regulatory science. We create reliable and robust approach for quality, efficacy and safety assessment of nanomaterials by combining experimental and computational tools. Our high-impact testing platform for more tailored risk assessment and decision making is based on advanced biochemistry, immunology, toxicology, molecular and cell biology facilities.